Skip to main content

Table 2 Base Case results (ref. Standard care)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy

Cost

Δ Cost

QALY

Δ QALY

ICER

Standard Care

33369.9

 

0.7673

  

Dexamethasone

33555.6

185.8

0.803

0.0357

5208

Remedesivir

32354.4

-1015.5

0.7734

0.0061

Dominant

Rem + Dex

32540.2

-829.71

0.809

0.0417

Dominant

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us